

Original Research

Received 01 July 2026

Revised 09 Aug 2026

Accepted 22 Aug 2026

Natural Resources for Human Health 2026, Vol. 6 (17s): 657–675

KEYWORDS:

Heart Failure; Sympathetic Nervous System; Renin Angiotensin Aldosterone System; Autonomic Dysfunction; β -Adrenergic Signaling; GRK2; Renal Denervation.

Neurohormonal Crosstalk in Heart Failure: Targeting the Sympathetic-RAAS Axis for Precision Therapeutics

Maryam^{1,3}, Mohammed Gulzar Ahmed², Ahmed Hasan Mohiuddin³, Sameera Tarannum³, Syed Hasan Mohiuddin³, Syed Ali⁴, Fathima¹

¹Department of Pharmacy Practice, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Ayush campus, Naringana, Deralakatte, Mangalore, Karnataka, India.

²Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Ayush campus, Naringana, Deralakatte, Mangalore, Karnataka, India.

³Department of Pharmacy Practice, Deccan School of Pharmacy, Nampally, Hyderabad, Telangana, India

⁴Department of Pharmacy Practice, Sultan-ul-Uloom College of Pharmacy, Banjara Hills, Hyderabad, Telangana, India

Corresponding Author: Dr. Mohammed Gulzar Ahmed

Principal & Dean, Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Karnataka, India.

Email: principalypcrc@yenepoya.edu.in ORCID iD:0000-0002-9226-9984

ABSTRACT: Heart failure (HF) is characterized by sustained autonomic imbalance marked by chronic sympathetic nervous system (SNS) activation and upregulation of the renin angiotensin aldosterone system (RAAS). While initially compensatory, persistent neurohormonal activation promotes adverse cardiac remodeling, arrhythmogenesis, renal sodium retention, and progressive ventricular dysfunction. Increasing evidence indicates that the SNS and RAAS function not as isolated pathways but as an integrated neurohormonal axis with bidirectional amplification mechanisms that accelerate HF progression.

This review synthesizes current understanding of sympathetic-RAAS crosstalk at molecular, cellular, and systemic levels. Mechanistic insights into β -adrenergic receptor desensitization, G protein-coupled receptor kinase 2 (GRK2) signaling, angiotensin II mediated sympathetic facilitation, aldosterone driven autonomic modulation, and renal sympathetic activation in congestion physiology are discussed. Established therapies including β blockers, angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors are examined through the lens of autonomic modulation rather than solely haemodynamic effects.

Additionally, device based strategies such as renal denervation, baroreceptor activation therapy, and vagal nerve stimulation are evaluated, highlighting translational data and clinical trial outcomes

Finally, we explore emerging precision targets, including GRK2 inhibition, central RAAS modulation, and neuroimmune interactions, proposing a framework for individualized

autonomic targeted therapy.

Understanding the integrated neurohormonal network may refine therapeutic strategies and improve outcomes across the HF spectrum.

Key Points:

1. Heart failure progression is driven by bidirectional crosstalk between the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS), forming a self-amplifying neurohormonal axis.
2. Chronic SNS and RAAS activation promotes adverse cardiac remodeling, oxidative stress, inflammation, fibrosis, and progressive ventricular dysfunction.
3. Current guideline-directed therapies including β -blockers, ARNIs, MRAs, and SGLT2 inhibitors, improve outcomes by interrupting maladaptive neurohormonal signaling.
4. Emerging therapies targeting GRK2, central RAAS signaling, renal denervation, and autonomic modulation offer promising precision-based approaches for heart failure management.
5. Future heart failure treatment should focus on individualized neurohormonal modulation using biomarkers and molecular profiling to optimize therapeutic response and improve clinical outcomes.

INTRODUCTION:

Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, affecting more than 64 million individuals and imposing a substantial socioeconomic burden across healthcare systems ⁽¹⁻²⁾. Despite advances in guideline-directed medical therapy, long-term prognosis remains guarded, with high rates of hospitalization, progressive ventricular dysfunction, and premature death ⁽³⁾. While hemodynamic impairment was historically considered central to HF pathophysiology, contemporary evidence underscores the pivotal role of neurohormonal dysregulation in driving disease progression ⁽⁴⁾.

A hallmark of HF is sustained autonomic imbalance characterized by heightened sympathetic nervous system (SNS) activity and withdrawal of parasympathetic tone ⁽⁵⁾. Initially compensatory, sympathetic activation maintains cardiac output through increased heart rate, contractility, and peripheral vasoconstriction. However, persistent adrenergic stimulation becomes maladaptive, contributing to β adrenergic receptor desensitization, intracellular calcium dysregulation, arrhythmogenesis, and adverse myocardial remodeling ⁽⁶⁾. Elevated circulating norepinephrine levels correlate with disease severity and independently predict mortality, emphasizing the pathophysiological importance of sympathetic overdrive ⁽⁷⁾.

Parallel to SNS activation, the renin-angiotensin-aldosterone system (RAAS) is persistently upregulated in HF ⁽⁸⁾. Reduced renal perfusion and sympathetic stimulation of juxtaglomerular cells promote renin release, leading to increased angiotensin II and aldosterone production ⁽⁹⁾. Angiotensin II exerts potent vasoconstrictive, pro-hypertrophic, pro-fibrotic, and pro-inflammatory effects, while aldosterone contributes to sodium retention, myocardial fibrosis, endothelial dysfunction, and vascular remodeling ⁽¹⁰⁾. Beyond systemic activation, tissue-level RAAS signaling within the myocardium, kidneys, and central nervous system further amplifies local pathological processes ⁽¹¹⁾.

Importantly, emerging evidence indicates that the SNS and RAAS do not operate as independent compensatory systems but rather function as an integrated and mutually reinforcing neurohormonal network ⁽¹²⁾. Angiotensin II enhances central sympathetic outflow and facilitates norepinephrine release at presynaptic terminals, while sympathetic stimulation augments renin secretion via β 1-adrenergic receptor activation, establishing a maladaptive positive feedback loop. This bidirectional amplification contributes to sustained hemodynamic stress, oxidative injury, neuroinflammation, and progressive ventricular remodeling ⁽¹³⁾.

Recognition of this interconnected axis has fundamentally shaped contemporary HF therapeutics. β -blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors confer clinical benefit in part through attenuation of maladaptive neurohormonal signaling rather than solely through hemodynamic modulation ⁽¹⁴⁾. In parallel, device-based

strategies targeting autonomic regulation such as renal denervation, baroreceptor activation therapy, and vagal nerve stimulation have emerged as potential adjunctive approaches ⁽¹⁵⁾.

Despite substantial progress, residual risk persists, and therapeutic responses vary considerably among individuals. This heterogeneity underscores the need for deeper mechanistic understanding of sympathetic-RAAS crosstalk and the development of precision autonomic targeted strategies. Elucidating the molecular, cellular, and central regulatory mechanisms sustaining chronic neurohormonal activation may refine risk stratification and enable individualized therapeutic interventions ⁽¹⁶⁾.

In this review, we synthesize current evidence on the integrated sympathetic-RAAS axis in HF, examine established and emerging therapeutic strategies through the lens of autonomic modulation, and explore future directions for precision neurohormonal targeting.

2. LITERATURE SEARCH STRATEGY

This narrative review was based on a structured literature search of PubMed/MEDLINE and Google Scholar covering publications from 1995 to 2026. Search terms combined controlled vocabulary and free text and included “heart failure,” “sympathetic nervous system,” “renin-angiotensin-aldosterone system,” “neurohormonal,” “ β -adrenergic receptor,” “GRK2,” “renal denervation,” “baroreflex activation therapy,” “vagus nerve stimulation,” and “precision medicine,” combined using Boolean operators. Eligible sources were peer-reviewed clinical trials, observational and physiological studies, preclinical studies, systematic and narrative reviews, and clinical practice guidelines published in English. Case reports and conference abstracts without full text were excluded. The literature search was conducted by one author with assistance from a second author, and the selected sources were reviewed by all authors. Because this is a narrative review, no formal risk-of-bias assessment or quantitative synthesis was performed. Instead, the evidence for each mechanism and intervention was graded by source and clinical maturity (Section 5.7).

3. SYMPATHETIC NERVOUS SYSTEM ACTIVATION IN HEART FAILURE:

Sustained activation of the SNS is a defining feature of HF and represents a central driver of disease progression. Although acute sympathetic stimulation initially preserves cardiac output by increasing heart rate, myocardial contractility, and peripheral vasoconstriction, persistent activation becomes maladaptive, contributing to ventricular remodeling, arrhythmogenesis, and cardiomyocyte injury ⁽¹⁷⁾.

Elevated plasma norepinephrine concentrations correlate strongly with HF severity and adverse clinical outcomes, establishing sympathetic overactivity as a key determinant of prognosis ⁽¹⁸⁾. Direct microneurographic study demonstrate increased muscle sympathetic nerve activity in patients with HF, reflecting intrinsic autonomic dysregulation rather than merely a secondary response to impaired cardiac output. These findings support the concept that SNS activation is a pathophysiological mechanism rather than a simple compensatory response ⁽¹⁹⁾.

3.1 Central Neural Drivers of Sympathetic Excitation:

Sympathetic hyperactivity in HF originates within central autonomic regulatory centers, including the hypothalamic paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and nucleus tractus solitarius (NTS). Enhanced excitatory signaling within these nuclei increases efferent sympathetic output to the heart, kidneys, and vasculature ⁽²⁰⁾.

The central renin-angiotensin system plays a crucial modulatory role. Angiotensin II acting within the brain stimulates NADPH oxidase dependent reactive oxygen species production, augmenting neuronal firing and impairing inhibitory nitric oxide signaling. This redox imbalance sustains sympathetic excitation and establishes a feed-forward loop of neurohormonal activation ⁽²¹⁾.

Peripheral reflex mechanisms further amplify sympathetic drive. Carotid body chemoreceptor hypersensitivity has been demonstrated in HF, contributing to enhanced sympathetic discharge and instability of respiratory control ⁽²²⁾. Importantly, exercise training can partially normalize these central reflex abnormalities, highlighting the plasticity of autonomic circuits ⁽²³⁾.

3.2 β -Adrenergic Receptor Dysregulation and Molecular Remodeling:

At the myocardial level, chronic catecholamine exposure induces β -adrenergic receptor (β -AR) desensitization and downregulation. Early human studies revealed reduced β_1 -adrenergic receptor density and impaired catecholamine responsiveness in failing hearts. This receptor dysfunction contributes directly to impaired contractile reserve ⁽²⁴⁾.

A central molecular mediator of β -AR desensitization is G-protein coupled receptor kinase 2 (GRK2). Increased myocardial GRK2 expression has been observed in HF and correlates with disease severity. GRK2 phosphorylates activated β -ARs, promoting receptor internalization and functional uncoupling ⁽²⁵⁾.

In transgenic mice, cardiac overexpression of β -adrenergic receptor kinase 1 (β ARK1/GRK2) impairs contractility, whereas GRK2 inhibition improves β -AR signaling and cardiac performance in experimental HF models, supporting a causal role for GRK2 in preclinical settings ^(26,27). These findings are preclinical: GRK2 inhibition has not been evaluated in clinical outcome trials in patients with HF and remains an investigational target.

3.3 Sympathetic-Renal Interactions and Neurohormonal Amplification:

Renal sympathetic activation represents a critical effector pathway of central SNS overdrive. Increased efferent renal nerve activity promotes renin release, sodium retention, and reduced renal perfusion. These changes directly stimulate activation of the renin-angiotensin-aldosterone system (RAAS) ⁽²⁸⁾.

Bidirectional amplification between the SNS and RAAS sustains neurohormonal activation. Angiotensin II enhances sympathetic neurotransmission, while norepinephrine stimulates renin secretion, establishing a self-perpetuating cycle of vasoconstriction and volume expansion ⁽²⁹⁾. This reciprocal interaction forms the foundation of the sympathetic-RAAS axis emphasized in this review.

Clinical investigations confirm that persistent sympathetic activation contributes to progressive renal dysfunction and worsened outcomes in HF. These observations provide mechanistic justification for combined neurohormonal blockade in contemporary HF therapy ⁽³⁰⁻³¹⁾. This reciprocal interaction forms the foundation of the sympathetic-RAAS axis illustrated in **Figure 1**.

3.4 Oxidative Stress, Neuroimmune Signaling, and Cellular Consequences:

Chronic sympathetic stimulation extends beyond hemodynamic effects to influence intracellular signaling pathways. Persistent β -AR activation increases intracellular calcium loading, mitochondrial stress, and reactive oxygen species generation ⁽³²⁾. Oxidative stress disrupts excitation-contraction coupling and promotes cardiomyocyte apoptosis ⁽³³⁾.

In parallel, sympathetic signaling interacts with innate immune pathways. Pro-inflammatory cytokines, including tumor necrosis factor- α and interleukin-6, are elevated in HF and may be partially driven by adrenergic mechanisms. This neuroimmune interaction accelerates myocardial remodeling and fibrosis ⁽³⁴⁾.

Mitochondrial dysfunction further impairs ATP production, reducing myocardial energetic efficiency and exacerbating contractile dysfunction. Thus, SNS activation represents a multi-level pathological process spanning neural regulation, receptor biology, redox signaling, and cellular survival ⁽³⁵⁾.

3.5 Therapeutic Implications:

Recognition of sustained sympathetic activation as a disease-amplifying mechanism transformed HF management. β -blockers attenuate catecholamine toxicity, restore receptor sensitivity, and improve survival outcomes ⁽³⁶⁾. Emerging strategies targeting central sympathetic outflow, GRK2 modulation, and renal sympathetic signaling represent potential precision therapeutic avenues ⁽³⁷⁾.

Rather than serving solely as a compensatory mechanism, SNS activation functions as a core pathological driver in HF. Effective therapeutic strategies therefore aim not merely to suppress symptoms but to interrupt maladaptive neurohormonal crosstalk within the sympathetic-RAAS axis ⁽³⁸⁾.

4. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ACTIVATION IN HEART FAILURE:

Activation of the RAAS represents a central neurohormonal mechanism in HF, functioning in close coordination with sympathetic overactivity. While initially compensatory preserving arterial pressure and organ perfusion-persistent RAAS

activation drives vasoconstriction, sodium retention, inflammation, fibrosis, and adverse ventricular remodeling. Contemporary understanding recognizes RAAS not merely as a circulating hormonal cascade but as a complex, tissue-level signaling network with central nervous system involvement ⁽³⁹⁾.

4.1 Systemic RAAS Activation: Initiation and Amplification:

Reduced renal perfusion pressure, heightened sympathetic renal nerve activity, and decreased sodium delivery to the macula densa stimulate renin release from juxtaglomerular cells ⁽⁴⁰⁾. Renin cleaves angiotensinogen to angiotensin I, which is subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE) ⁽⁴¹⁾.

Angiotensin II exerts potent vasoconstrictive effects via angiotensin type 1 (AT1) receptors, increasing systemic vascular resistance and afterload. In parallel, it stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention and contributing to volume expansion ⁽⁴²⁾. Although these mechanisms initially support perfusion, sustained activation increases myocardial wall stress and accelerates structural remodeling ⁽⁴³⁾.

Seminal clinical trials established the pathological relevance of RAAS activation. ACE inhibition significantly reduced mortality and hospitalization in HF, demonstrating that RAAS blockade modifies disease progression rather than simply alleviating symptoms. These findings positioned RAAS suppression as a foundational therapeutic principle ⁽⁴⁴⁾.

4.2 Local (Tissue) RAAS and Cardiac Remodeling:

Beyond systemic effects, local RAAS activation within the myocardium plays a critical role in structural and molecular remodeling. Cardiac fibroblasts and myocytes express components of the RAAS, allowing angiotensin II generation within cardiac tissue independent of circulating levels ⁽⁴⁵⁾.

Angiotensin II promotes hypertrophy, fibroblast proliferation, collagen deposition, and extracellular matrix remodeling through activation of mitogen-activated protein kinase (MAPK) pathways and transforming growth factor- β signaling. These effects contribute to ventricular stiffening, diastolic dysfunction, and progressive systolic impairment ⁽⁴⁶⁾.

Additionally, angiotensin II enhances oxidative stress via NADPH oxidase activation, increasing reactive oxygen species (ROS) production ⁽⁴⁷⁾. Oxidative stress not only damages cellular structures but also amplifies sympathetic signaling and inflammatory pathways, linking RAAS activation directly to neurohormonal crosstalk ⁽⁴⁸⁾.

4.3 Aldosterone and Mineralocorticoid Receptor Signaling:

Aldosterone exerts effects beyond sodium retention. Activation of mineralocorticoid receptors (MRs) in cardiomyocytes, fibroblasts, and vascular cells promotes inflammation, oxidative stress, endothelial dysfunction, and myocardial fibrosis ⁽⁴⁹⁾.

Clinical evidence from mineralocorticoid receptor antagonist trials demonstrated substantial reductions in morbidity and mortality, confirming aldosterone's pathological significance in HF progression ⁽⁵⁰⁾. These benefits occur even when patients are already receiving ACE inhibitors, indicating incomplete RAAS suppression and highlighting the concept of “aldosterone escape” ⁽⁵¹⁾.

Emerging data suggest that mineralocorticoid receptor activation within the central nervous system may also enhance sympathetic drive, further integrating RAAS and SNS signaling. This reinforces the concept of neurohormonal amplification rather than isolated hormonal pathways ⁽⁵²⁾.

4.4 Alternative RAAS Pathways: ACE2 and Angiotensin-(1-7):

The classical ACE-angiotensin II-AT1 receptor axis is counterbalanced by the ACE2-angiotensin-(1-7)-Mas receptor pathway, which exerts vasodilatory, anti-fibrotic, and anti-inflammatory effects. ACE2 converts angiotensin II into angiotensin-(1-7), shifting signaling toward protective pathways ⁽⁵³⁾.

In HF, this protective axis is often downregulated, resulting in dominance of the deleterious angiotensin II-AT1 pathway. Augmenting ACE2 activity or angiotensin-(1-7) signaling has therefore emerged as a potential therapeutic strategy ⁽⁵⁴⁾.

The development of angiotensin receptor-neprilysin inhibitors (ARNIs) represents a translational advance targeting multiple neurohormonal pathways simultaneously. By combining AT1 receptor blockade with neprilysin inhibition, these agents

enhance natriuretic peptide activity while suppressing RAAS signaling, leading to superior outcomes compared to ACE inhibition alone ⁽⁵⁵⁾.

4.5 RAAS-Sympathetic Crosstalk:

RAAS activation and sympathetic excitation are tightly interwoven. Angiotensin II enhances central sympathetic outflow by acting within autonomic regulatory nuclei, increasing neuronal excitability and ROS production ⁽⁵⁶⁾. Peripherally, angiotensin II facilitates norepinephrine release from sympathetic nerve terminals and reduces its reuptake ⁽⁵⁷⁾.

Conversely, sympathetic stimulation increases renin secretion via β_1 -adrenergic receptor activation in juxtaglomerular cells. This bidirectional amplification establishes the sympathetic-RAAS axis as a self-reinforcing neurohormonal circuit central to HF pathophysiology ⁽⁵⁾.

Disruption of this axis through combined β -blockade and RAAS inhibition forms the mechanistic basis of modern HF therapy. Precision therapeutics increasingly aim to modulate this crosstalk at multiple nodes, including receptor signaling, intracellular kinase pathways, and redox balance ⁽⁵⁸⁾. These bidirectional interactions are summarized schematically in **Figure 1**.

4.6 Therapeutic Implications and Precision Approaches:

Targeting RAAS remains foundational in HF management. ACE inhibitors, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists, and ARNIs reduce mortality and hospitalization. However, interindividual variability in response suggests underlying heterogeneity in neurohormonal activation ⁽⁵⁹⁾.

Biomarker-guided therapy, genetic profiling of RAAS components, and molecular targeting of downstream effectors such as oxidative stress pathways represent emerging precision strategies ⁽⁶⁰⁾. Understanding RAAS activation within the broader framework of neurohormonal crosstalk is therefore critical to advancing individualized HF treatment.

5. INTEGRATED SYMPATHETIC-RAAS CROSSTALK MODEL IN HEART FAILURE:

HF is characterized by coordinated activation of the SNS and the RAAS, which function as an integrated neurohormonal network rather than isolated pathways. Early conceptual models of HF emphasized hemodynamic impairment; however, subsequent work established that persistent neurohormonal activation drives disease progression independently of initial cardiac dysfunction ⁽⁶¹⁾. Contemporary evidence supports the view that the sympathetic-RAAS axis forms a self-reinforcing circuit central to HF pathophysiology ⁽⁵⁾. **Figure 1** provides an integrated overview of the reciprocal interactions between central sympathetic activation, cardiac and renal neurohormonal responses, RAAS activation, bidirectional amplification loops, and the principal therapeutic targets that interrupt this maladaptive signaling network.




Figure 1. Integrated Sympathetic–RAAS Axis in Heart Failure.

Chronic activation of the sympathetic nervous system (SNS) enhances cardiac β -adrenergic signaling and renal sympathetic nerve activity, leading to adverse cardiac remodeling, sodium and water retention, and activation of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II and aldosterone further augment central and peripheral sympathetic activity, establishing a self-perpetuating bidirectional neurohormonal amplification loop that accelerates heart failure progression. The figure also highlights established and emerging therapeutic strategies targeting different levels of the axis, including β -blockers, angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), sodium-glucose cotransporter 2 (SGLT2) inhibitors, renal denervation, baroreflex activation therapy, and emerging molecular targets such as GRK2 inhibition and central RAAS modulation.

5.1 Central Nervous System Integration:

Within central autonomic nuclei such as the paraventricular nucleus (PVN) and rostral ventrolateral medulla (RVLM), angiotensin II enhances neuronal excitability and sympathetic outflow through AT1 receptor activation and NADPH oxidase-mediated reactive oxygen species (ROS) generation. This redox-sensitive signaling amplifies efferent sympathetic discharge to the heart, kidneys, and vasculature ^(62,63).

Kishi and et.al., described novel mechanisms of central sympathetic regulation in HF, emphasizing that oxidative stress and inflammatory mediators sustain neuronal hyperactivity even in the absence of ongoing hemodynamic triggers ⁽⁶⁴⁾. Mineralocorticoid receptor activation within the brain further augments sympathetic tone, demonstrating that RAAS components act directly within central autonomic circuits ⁽⁶⁵⁾.

Parati and et al., highlighted the re-emergence of the SNS as a central therapeutic target in cardiovascular medicine, underscoring the clinical importance of central-peripheral integration. Collectively, these findings position the brain as a critical hub of neurohormonal crosstalk ⁽⁶⁶⁾.

5.2 Peripheral Neurohormonal Amplification:

At the peripheral level, bidirectional reinforcement between SNS and RAAS sustains maladaptive activation. β_1 -adrenergic stimulation of juxtaglomerular cells increases renin secretion, initiating RAAS cascade activation ⁽⁶⁷⁾. Conversely, angiotensin II facilitates norepinephrine release from sympathetic nerve terminals and impairs its reuptake, intensifying adrenergic signaling ⁽⁶⁸⁾.

Schlaich and colleagues demonstrated that heightened cardiac sympathetic activity correlates with structural remodeling, reinforcing the link between neurohormonal activation and ventricular hypertrophy ⁽⁶⁹⁾. Grassi et al. further confirmed that sympathetic overactivity is not merely compensatory but contributes directly to adverse outcomes in HF ⁽⁷⁰⁾.

Thus, the SNS and RAAS engage in a positive feedback loop:

SNS activation $\rightarrow$ $\uparrow$ Renin $\rightarrow$ $\uparrow$ Angiotensin II

Angiotensin II $\rightarrow$ $\uparrow$ Central & peripheral SNS activity

This cycle perpetuates vasoconstriction, sodium retention, and myocardial stress.

5.3 Molecular Convergence: Oxidative Stress, Inflammation, and Fibrosis

The convergence of SNS and RAAS extends to intracellular signaling pathways. Angiotensin II activates NADPH oxidase and downstream inflammatory cascades ⁽⁷¹⁾. Forrester et al. provided a comprehensive update on angiotensin II signal transduction, detailing its roles in oxidative stress, vascular dysfunction, and fibrosis ⁽⁴²⁾.

Simultaneously, chronic β -adrenergic stimulation promotes mitochondrial dysfunction and ROS generation. These overlapping redox pathways impair calcium handling and energy metabolism, accelerating cardiomyocyte apoptosis ⁽⁷²⁾.

Angiotensin II also exerts immunomodulatory effects, linking RAAS activation to vascular and myocardial inflammation. This neuroimmune interface aligns with the broader inflammatory hypothesis of HF progression ⁽⁵⁾. Molecular convergence therefore transforms neurohormonal activation into structural remodeling and fibrosis ⁽⁷³⁾.

5.4 Evolution of the Neurohormonal Model:

The transition from hemodynamic to neurohormonal paradigms marked a turning point in HF management. Early recognition that neurohormonal activation independently worsens outcomes led to trials targeting both SNS and RAAS ⁽¹²⁾.

Guideline-directed therapy now reflects this integrated understanding. The 2021 European Society of Cardiology (ESC) guidelines and 2022 AHA/ACC/HFSA guidelines emphasize combined neurohormonal blockade as foundational therapy in HF ⁽⁷⁴⁾. These recommendations underscore that interrupting sympathetic-RAAS crosstalk is essential for disease modification.

5.5 Therapeutic Disruption of the Sympathetic-RAAS Axis:

Modern HF therapy targets multiple nodes of the integrated axis:

1. β -blockers reduce catecholamine toxicity and renin release ⁽⁷⁵⁾.
2. ACE inhibitors and ARBs suppress angiotensin II signaling ⁽⁷⁶⁾.
3. Mineralocorticoid receptor antagonists counteract aldosterone-mediated fibrosis ⁽⁷⁷⁾.
4. ARNIs enhance natriuretic peptide signaling while inhibiting RAAS ⁽⁷⁸⁾.

Beyond traditional blockade, heart rate modulation with ivabradine demonstrated outcome benefits in patients with persistent sympathetic activation ⁽⁷⁹⁾. More recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown robust reductions in HF hospitalization and mortality, possibly through indirect neurohormonal and metabolic modulation ⁽⁸⁰⁾.

These advances illustrate that optimal therapy requires simultaneous attenuation of interconnected pathways rather than isolated receptor targeting. The multiple pharmacological and device-based intervention points within the integrated sympathetic-RAAS axis are highlighted in **Figure 1**.

5.6 Toward Precision Neurohormonal Modulation:

Although neurohormonal blockade is broadly effective, interindividual variability in response suggests heterogeneity in axis activation. Emerging strategies aim to refine therapeutic targeting through biomarker profiling, autonomic function assessment, and molecular pathway characterization ⁽⁷⁸⁾.

Central RAAS modulation, GRK2 inhibition, and targeted reduction of oxidative stress represent potential precision approaches. As understanding of neurohormonal crosstalk deepens, therapeutic strategies may evolve from uniform suppression toward individualized modulation of dominant pathological drivers ⁽⁸¹⁾.

5.7 Evidence Maturity of the Mechanistic Framework

To distinguish established physiology from emerging hypotheses, evidence for each element of the axis is graded as follows. Tier 1: human evidence from randomized trials showing clinical outcome benefit. Tier 2: human physiological or observational evidence, or randomized trials limited to surrogate or functional endpoints. Tier 3: evidence derived mainly from animal models or in vitro studies. Tier 4: mechanistic hypothesis not directly tested in HF. Table 1 applies this grading to the mechanisms discussed in this review.

Table 1. Evidence maturity of mechanisms in the sympathetic–RAAS axis

Mechanism	Principal evidence	Tier	References
Increased sympathetic activity and elevated norepinephrine, associated with prognosis	Human microneurography and plasma norepinephrine cohorts	2	18, 19
β -AR downregulation and desensitization in failing myocardium	Human myocardial tissue studies	2	24
Increased myocardial	Human myocardial	2	25

GRK2 expression correlating with severity	tissue		
Causal role of GRK2 in cardiac dysfunction	Transgenic and experimental animal models	3	26, 27
Renal sympathetic activation driving renin release and sodium retention	Human and animal physiology	2	28, 40
Angiotensin II facilitation of norepinephrine release (bidirectional loop)	Human physiological and animal studies	2–3	56, 57, 68
Central AT1/NADPH-oxidase/ROS signaling in PVN and RVLM	Animal HF models	3	21, 62, 63
Central mineralocorticoid receptor activation augmenting sympathetic tone	Predominantly animal studies	3	52, 65
Aldosterone/MR-driven fibrosis and benefit of MRA	Randomized trials in HFrEF	1	49–51
ACE2–angiotensin-(1-7)–Mas protective axis	Preclinical, limited human data	3	53, 54
Adrenergic-driven oxidative, mitochondrial and inflammatory injury	Preclinical and human biomarker studies	3	32–35
Neuroimmune interface sustaining neurohormonal activation	Largely hypothetical in HF	4	34

6. PRECISION THERAPEUTICS AND FUTURE DIRECTIONS:

The recognition of HF as a disorder of integrated neurohormonal dysregulation has transformed therapeutic strategies over the past three decades. Contemporary management relies on simultaneous attenuation of the SNS and RAAS, yet substantial interindividual variability in disease progression and treatment response persists. These observations highlight the need to move beyond uniform neurohormonal blockade toward precision modulation of dominant pathological pathways within the sympathetic-RAAS axis ⁽⁸²⁾.

6.1 Stratifying Neurohormonal Activation:

HF is biologically heterogeneous. Some patients exhibit pronounced sympathetic overactivity, while others demonstrate dominant RAAS-driven remodeling or inflammatory phenotypes. Circulating biomarkers such as plasma norepinephrine, renin activity, aldosterone levels, natriuretic peptides, and inflammatory cytokines may provide insight into individualized neurohormonal profiles ⁽⁸³⁾.

Advanced autonomic assessment techniques including heart rate variability, baroreflex sensitivity, and microneurography offer mechanistic characterization of sympathetic tone. Integration of these physiological measures with molecular biomarkers may enable stratification of patients based on axis predominance ⁽⁸⁴⁾.

Future precision frameworks may classify HF not solely by ejection fraction but by neurohormonal activation patterns, thereby guiding tailored intervention intensity and pathway prioritization ⁽⁸⁵⁾.

These approaches remain investigational. Plasma norepinephrine, renin and aldosterone vary with posture, medications and renal function; microneurography is invasive and not widely available; and heart rate variability is influenced by β -blockers, atrial fibrillation and age.

6.2 Targeting Central Neurohormonal Mechanisms:

Accumulating evidence indicates that central autonomic dysregulation sustains sympathetic excitation even when peripheral hemodynamics are corrected ⁽⁸⁶⁾. Therapeutic strategies targeting central RAAS signaling and oxidative stress pathways have shown promise in experimental models ⁽⁸⁷⁾.

Neuromodulatory approaches including renal sympathetic denervation and baroreceptor activation therapy represent attempts to directly modulate autonomic circuits. Although clinical results have been variable, ongoing refinement of patient selection criteria and device technology may enhance efficacy ⁽⁸⁸⁾.

Central mineralocorticoid receptor modulation and redox-sensitive signaling inhibition also represent potential strategies to disrupt maladaptive feed-forward loops within autonomic nuclei ⁽⁸⁹⁾.

6.3 Molecular Precision: GRK2 and Intracellular Signaling:

At the intracellular level, dysregulated β -adrenergic receptor signaling mediated by G-protein-coupled receptor kinase 2 (GRK2) provides a compelling precision target. Elevated GRK2 expression contributes to receptor desensitization and contractile dysfunction. Experimental inhibition of GRK2 restores β -adrenergic responsiveness and improves cardiac performance, suggesting therapeutic potential beyond traditional β -blockade ⁽⁹⁰⁾.

Similarly, targeting angiotensin II-induced oxidative stress and inflammatory signaling cascades may allow selective modulation of downstream remodeling pathways while preserving necessary physiological responses ⁽⁹¹⁾.

Emerging pharmacologic strategies aimed at mitochondrial protection, redox balance, and fibrosis attenuation may complement neurohormonal blockade by addressing intracellular convergence points ⁽⁹²⁾.

Their clinical benefit in HF is well established in randomized trials across ejection-fraction ranges; whether it is mediated through attenuation of sympathetic–RAAS signaling remains unproven. Proposed contributions include effects on neurohormonal activation, myocardial energetics and oxidative stress, but these are mechanistic hypotheses supported mainly by experimental and small human studies ⁽⁹⁴⁾.

6.4 Expanding the Therapeutic Network:

The evolution of HF therapy increasingly reflects recognition of network-level interactions. Angiotensin receptor–neprilysin inhibition exemplifies dual-pathway modulation, simultaneously suppressing RAAS and enhancing natriuretic peptide signaling ⁽⁹³⁾.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors further expand the paradigm. Beyond glycemic effects, these agents appear to modulate neurohormonal activation, improve myocardial energetics, and reduce oxidative stress. Their consistent benefit across HF phenotypes suggests indirect stabilization of maladaptive neurohormonal crosstalk ⁽⁹⁴⁾.

Heart rate modulation with ivabradine provides additional refinement by targeting persistent sympathetic-mediated tachycardia. Collectively, these therapies illustrate a shift from isolated receptor antagonism toward multidimensional pathway optimization ⁽⁹⁵⁾.

Table 2 compares established and investigational interventions by their target on the axis, key evidence and clinical maturity.

Table 2. Interventions targeting the sympathetic–RAAS axis: evidence and maturity

Intervention	Axis target	Evidence base	Demonstrated effect	Maturity
β -blockers	Sympathetic β -AR signaling; renin release	Randomized trials and reviews in HFrEF	Lower mortality and HF hospitalization	Tier 1 in HFrEF
ACE inhibitors / ARBs	Angiotensin II signaling	Randomized trials and reviews in HFrEF	Lower mortality and HF hospitalization	Tier 1 in HFrEF
ARNI	AT1 blockade plus neprilysin inhibition	Randomized trials versus ACE inhibition and reviews	Superior outcomes compared with ACE inhibition alone	Tier 1 in HFrEF
MRAs	Aldosterone–MR signaling; central effects hypothesized	Randomized trials and meta-analysis	Lower morbidity and mortality, including on top of ACE inhibitors	Tier 1 in HFrEF
SGLT2 inhibitors	Neurohormonal effect proposed but unproven	Randomized trials and reviews	Lower HF hospitalization and mortality	Tier 1 for outcomes; Tier 4 for axis mechanism
Ivabradine	Sinus-node If inhibition; not a direct sympatholytic	Randomized trial evidence and review	Heart rate reduction with outcome benefit in selected patients	Tier 1 in selected HFrEF
Baroreflex activation therapy	Reduces sympathetic outflow	Device trials and reviews	Functional improvement in selected HFrEF; mortality and hospitalization benefit not established	Tier 2; adjunctive
Vagus nerve stimulation	Increases parasympathetic tone	Device trials and reviews	Outcome benefit not demonstrated	Tier 2; investigational
Renal denervation	Reduces renal sympathetic activity	Small feasibility and early-phase studies	No outcome data in HF	Tier 2; investigational
GRK2 inhibition	Restores β -AR responsiveness	Animal models	None in humans	Tier 3; preclinical

6.5 Systems Biology and Computational Modeling:

Advances in systems biology offer an opportunity to map the dynamic interactions within the sympathetic-RAAS axis. Computational modeling of neurohormonal networks may predict therapeutic responsiveness and identify dominant nodes within individual patients.

Integration of transcriptomic, proteomic, and metabolomic data could further delineate molecular signatures associated with sympathetic or RAAS predominance. Such approaches align with broader cardiovascular precision medicine initiatives emphasized in contemporary guidelines ⁽⁹⁶⁾.

Artificial intelligence-driven phenotyping may eventually allow real-time personalization of neurohormonal modulation strategies ⁽⁹⁷⁾.

6.6 Future Directions:

Several key areas warrant further investigation:

1. Central RAAS-SNS modulation: Translating experimental central-targeting strategies into safe clinical therapies.
2. Biomarker-guided titration: Developing validated algorithms to individualize neurohormonal blockade intensity.
3. Molecular pathway targeting: Advancing GRK2 inhibitors, redox modulators, and antifibrotic therapies.
4. Neuroimmune integration: Clarifying the role of inflammatory signaling in sustaining neurohormonal activation.
5. Phenotype-specific strategies: Tailoring therapies across HF with reduced, mildly reduced, and preserved ejection fraction.

Future research must integrate mechanistic neuroscience, cardiovascular biology, and translational therapeutics to refine axis-targeted interventions.

6.7 Heterogeneity Across HF Phenotypes, Comorbidities and Treatment Interactions

The evidence for neurohormonal blockade is strongest in HFrEF, and the sympathetic–RAAS framework should not be assumed to apply uniformly across phenotypes. In HFrEF, β -blockers, RAAS inhibitors, ARNI and MRAs reduce mortality and hospitalization, whereas at higher ejection fractions the benefits of these agents are smaller or less consistent in randomized trials; SGLT2 inhibitors are the main therapy with benefit across the ejection-fraction spectrum. In HFpEF, sympathetic and RAAS activation may be shaped by comorbid hypertension, obesity, diabetes and chronic kidney disease ^(19,38). Aetiology (ischemic versus non-ischemic), age, sex, frailty and care setting may further modify neurohormonal profiles and treatment response, and these subgroups remain under-represented in mechanistic and clinical studies.

Comorbidities also constrain which axis-targeted therapies can be used. Chronic kidney disease and hyperkalemia limit MRA and ARNI use; symptomatic hypotension limits titration of RAAS-active agents; bradycardia and conduction disease limit β -blockers and ivabradine; and reactive airway disease may complicate β -blocker therapy.

Treatment interactions also require attention. ARNI must not be combined with ACE inhibitors because of the risk of angioedema, and a 36-hour washout is required when switching. MRAs combined with ACE inhibitors, ARBs or ARNI increase the risk of hyperkalemia and renal impairment. Ivabradine added to a β -blocker increases the risk of bradycardia, and SGLT2 inhibitors combined with diuretics may cause volume depletion. Device therapies (BAT, VNS and renal denervation) may add to drug-induced hypotension or bradycardia, and their incremental benefit on top of contemporary combination therapy has been little studied.

6.8 Limitations of the Current Evidence

Several limitations constrain the translation of this framework into individualized care. First, this is a narrative review and is subject to selection bias. Second, much of the mechanistic evidence for central RAAS signaling, GRK2 and neuroimmune pathways derives from animal models or from hypertension and other non-HF settings, so extrapolation to human HF is uncertain. Third, there is no validated, widely available measure of sympathetic or RAAS predominance, and no accepted thresholds for classifying patients. Fourth, no trial has randomized patients to therapy according to axis predominance; autonomic-targeted individualization therefore remains hypothesis-generating. Fifth, the data for device-based and investigational therapies are limited by small samples, heterogeneous patient selection and varied endpoints. Finally, many pivotal drug trials were conducted before current combination therapy, so the incremental value of additional axis-targeted interventions is uncertain.

7. CONCLUSION

Heart failure is fundamentally a disorder of maladaptive neurohormonal crosstalk. The sympathetic-RAAS axis operates as a dynamic, self-amplifying network that links central autonomic dysregulation to peripheral hemodynamic stress, oxidative injury, inflammation, and structural remodeling.

Precision therapeutics in HF will require moving beyond uniform suppression toward individualized modulation of dominant neurohormonal drivers. By targeting central integration, peripheral amplification, and molecular convergence points, future strategies may more effectively disrupt pathological feedback loops and improve long-term outcomes.

Understanding and refining modulation of the sympathetic-RAAS axis therefore represents a critical frontier in cardiovascular neuroscience and translational heart failure therapy.

DISCLOSURES:

FUNDING: No external funding was used in the preparation of this manuscript.

CONFLICT OF INTEREST: All authors have no potential conflicts of interest that might be relevant to the contents of this manuscript.

AUTHORS' CONTRIBUTIONS: M. conceived the review, conducted the literature search, synthesized the evidence, drafted the manuscript, and prepared the figures. M.G.A. conceptualized the study, supervised the work, critically reviewed the manuscript, and provided intellectual input. G.R.R. contributed to the clinical interpretation of the literature, reviewed the manuscript, and provided expert cardiology input. F. assisted with the literature review, manuscript editing, and reference management. A.H.M. contributed to manuscript revision and critically reviewed the content. All authors reviewed and approved the final manuscript.

DATA AVAILABILITY STATEMENT: Not applicable.

ETHICS APPROVAL: Not applicable.

CODE AVAILABILITY: Not applicable.

CONSENT TO PARTICIPATE: Not applicable.

CONSENT FOR PUBLICATION: Not applicable.

References:

- [1] Savarese, G., & Lund, L. H. (2017). Global Public Health Burden of Heart Failure. *Cardiac failure review*, 3(1), 7–11. <https://doi.org/10.15420/cfr.2016:25:2>
- [2] .Maryam, Varghese, T.P. & Tazneem, B. Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations. *Am J Cardiovasc Drugs* 26, 165–177 (2026). <https://doi.org/10.1007/s40256-025-00771-8>
- [3] Maryam (2026). Bridging evidence and practice in heart failure care: barriers and pragmatic solutions to guideline-directed medical therapy implementation in India and other low-resource settings. *Naunyn-Schmiedeberg's archives of pharmacology*, 10.1007/s00210-026-05594-1. Advance online publication. <https://doi.org/10.1007/s00210-026-05594-1>
- [4] Maryam, Varghese, T. P., Tazneem, B., & Reddy, G. R. (2025). Emerging Role of Weight-Loss Medications in the Management of Heart Failure: Current Evidence and Future Perspectives. *American journal of cardiovascular drugs : drugs, devices, and other interventions*, 25(5), 593–600. <https://doi.org/10.1007/s40256-025-00735-y>
- [5] Maryam, Varghese, T. P., & B, T. (2024). Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). *Current problems in cardiology*, 49(4), 102411. <https://doi.org/10.1016/j.cpcardiol.2024.102411>
- [6] Du X. (2021). Sympatho-adrenergic mechanisms in heart failure: new insights into pathophysiology. *Medical review* (2021), 1(1), 47–77. <https://doi.org/10.1515/mr-2021-0007>

- [7] Borovac, J. A., D'Amario, D., Bozic, J., & Glavas, D. (2020). Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers. *World journal of cardiology*, 12(8), 373–408. <https://doi.org/10.4330/wjc.v12.i8.373>
- [8] Manolis, A. A., Manolis, T. A., & Manolis, A. S. (2023). Neurohumoral Activation in Heart Failure. *International journal of molecular sciences*, 24(20), 15472. <https://doi.org/10.3390/ijms242015472>
- [9] Siragy, H. M., & Carey, R. M. (2010). Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. *American journal of nephrology*, 31(6), 541–550. <https://doi.org/10.1159/000313363>
- [10] Valentini, A., Heilmann, R. M., Kühne, A., Biagini, L., De Bellis, D., & Rossi, G. (2025). The Renin-Angiotensin-Aldosterone System (RAAS): Beyond Cardiovascular Regulation. *Veterinary sciences*, 12(8), 777. <https://doi.org/10.3390/vetsci12080777>
- [11] Cosarderelioglu, C., & Abadir, P. M. (2025). Revisiting renin-angiotensin-aldosterone system in aging: translational insights from bench to bedside and back. *The Journal of clinical investigation*, 135(21), e195633. <https://doi.org/10.1172/JCI195633>
- [12] Hartupee, J., & Mann, D. L. (2017). Neurohormonal activation in heart failure with reduced ejection fraction. *Nature reviews. Cardiology*, 14(1), 30–38. <https://doi.org/10.1038/nrcardio.2016.163>
- [13] Tsuda K. (2012). Renin-Angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension. *International journal of hypertension*, 2012, 474870. <https://doi.org/10.1155/2012/474870>
- [14] Iacoviello, M., Maria Sarullo, F., Bilato, C., Correale, M., Di Gesaro, G., Driussi, M., Passantino, A., Villani, A., & Di Lenarda, A. (2025). Improving the Management of Patients with Heart Failure with Reduced Ejection Fraction in Clinical Practice: The Case for Angiotensin Receptor-Neprilysin Inhibitor. *Cardiac failure review*, 11, e16. <https://doi.org/10.15420/cfr.2024.39>
- [15] Hucker, W. J., Singh, J. P., Parks, K., & Armoundas, A. A. (2014). Device-Based Approaches to Modulate the Autonomic Nervous System and Cardiac Electrophysiology. *Arrhythmia & electrophysiology review*, 3(1), 30–35. <https://doi.org/10.15420/aer.2011.3.1.30>
- [16] Zhang, F., Zhang, X., Jian, J., Zeng, X., Zheng, C., Zhang, Y., & Gao, J. (2025). Heart failure: mechanistic insights and precision therapeutic strategies. *Frontiers in cardiovascular medicine*, 12, 1696793. <https://doi.org/10.3389/fcvm.2025.1696793>
- [17] Zhang, D. Y., & Anderson, A. S. (2014). The sympathetic nervous system and heart failure. *Cardiology clinics*, 32(1), 33–vii. <https://doi.org/10.1016/j.ccl.2013.09.010>
- [18] Benedict, C. R., Shelton, B., Johnstone, D. E., Francis, G., Greenberg, B., Konstam, M., Probstfield, J. L., & Yusuf, S. (1996). Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. *Circulation*, 94(4), 690–697. <https://doi.org/10.1161/01.cir.94.4.690>
- [19] Chang, J. W., & Ramchandra, R. (2025). The sympathetic nervous system in heart failure with preserved ejection fraction. *Heart failure reviews*, 30(1), 209–218. <https://doi.org/10.1007/s10741-024-10456-0>
- [20] Xu, B., & Li, H. (2015). Brain mechanisms of sympathetic activation in heart failure: Roles of the renin-angiotensin system, nitric oxide and pro-inflammatory cytokines (Review). *Molecular medicine reports*, 12(6), 7823–7829. <https://doi.org/10.3892/mmr.2015.4434>
- [21] Su, C., Xue, J., Ye, C., & Chen, A. (2021). Role of the central renin-angiotensin system in hypertension (Review). *International journal of molecular medicine*, 47(6), 95. <https://doi.org/10.3892/ijmm.2021.4928>
- [22] Schultz, H. D., Marcus, N. J., & Del Rio, R. (2015). Mechanisms of carotid body chemoreflex dysfunction during heart failure. *Experimental physiology*, 100(2), 124–129. <https://doi.org/10.1113/expphysiol.2014.079517>

- [23] Pereyra, K.V., Schwarz, K.G., Diaz-Jara, E. et al. Peripheral chemoreceptors sustain central chemoreflex potentiation and cardiorespiratory abnormalities in high-output heart failure. *Basic Res Cardiol* 121, 113–127 (2026). <https://doi.org/10.1007/s00395-025-01154-5>
- [24] Mahmood, A., Ahmed, K., & Zhang, Y. (2022). β -Adrenergic Receptor Desensitization/Down-Regulation in Heart Failure: A Friend or Foe?. *Frontiers in cardiovascular medicine*, 9, 925692. <https://doi.org/10.3389/fcvm.2022.925692>
- [25] Woodall, M. C., Ciccarelli, M., Woodall, B. P., & Koch, W. J. (2014). G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. *Circulation research*, 114(10), 1661–1670. <https://doi.org/10.1161/CIRCRESAHA.114.300513>
- [26] Koch, W. J., Rockman, H. A., Samama, P., Hamilton, R. A., Bond, R. A., Milano, C. A., & Lefkowitz, R. J. (1995). Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. *Science (New York, N.Y.)*, 268(5215), 1350–1353. <https://doi.org/10.1126/science.7761854>
- [27] Mangmool, S., Parichatikanond, W., & Kurose, H. (2018). Therapeutic Targets for Treatment of Heart Failure: Focus on GRKs and β -Arrestins Affecting β AR Signaling. *Frontiers in pharmacology*, 9, 1336. <https://doi.org/10.3389/fphar.2018.01336>
- [28] Kiuchi, M. G., Ho, J. K., Nolde, J. M., Gavidia, L. M. L., Carnagarin, R., Matthews, V. B., & Schlaich, M. P. (2020). Sympathetic Activation in Hypertensive Chronic Kidney Disease - A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?. *Frontiers in physiology*, 10, 1546. <https://doi.org/10.3389/fphys.2019.01546>
- [29] Miller, A. J., & Arnold, A. C. (2019). The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications. *Clinical autonomic research : official journal of the Clinical Autonomic Research Society*, 29(2), 231–243. <https://doi.org/10.1007/s10286-018-0572-5>
- [30] Alvi, A., Singamala, H., Gadde, S. S. V., & Javvaji, C. K. (2026). The Intersection of Heart Failure and Chronic Kidney Disease: Challenges in Co-management. *Cureus*, 18(1), e100993. <https://doi.org/10.7759/cureus.100993>
- [31] von Lueder, T. G., Kotecha, D., Atar, D., & Hopper, I. (2017). Neurohormonal Blockade in Heart Failure. *Cardiac failure review*, 3(1), 19–24. <https://doi.org/10.15420/cfr.2016:22:2>
- [32] Du X. (2021). Sympatho-adrenergic mechanisms in heart failure: new insights into pathophysiology. *Medical review* (2021), 1(1), 47–77. <https://doi.org/10.1515/mr-2021-0007>
- [33] D'Oria, R., Schipani, R., Leonardini, A., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020). The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. *Oxidative medicine and cellular longevity*, 2020, 5732956. <https://doi.org/10.1155/2020/5732956>
- [34] Li, H., Chen, C., & Wang, D. W. (2021). Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure. *Frontiers in physiology*, 12, 695047. <https://doi.org/10.3389/fphys.2021.695047>
- [35] Yang H. M. (2025). Mitochondrial Dysfunction in Cardiovascular Diseases. *International journal of molecular sciences*, 26(5), 1917. <https://doi.org/10.3390/ijms26051917>
- [36] Guo, W., Li, H. Y., Li, H. X., Nie, Q. W., Wang, Z. H., Li, J. H., & Tang, Q. (2025). Sympathetic overactivation and catecholamine toxicity: mechanisms and therapeutic strategies for neurogenic heart injury following acute ischemic stroke. *Frontiers in cardiovascular medicine*, 12, 1632704. <https://doi.org/10.3389/fcvm.2025.1632704>
- [37] Rudomanova, V., & Blaxall, B. C. (2017). Targeting GPCR-G $\beta\gamma$ -GRK2 signaling as a novel strategy for treating cardiorenal pathologies. *Biochimica et biophysica acta. Molecular basis of disease*, 1863(8), 1883–1892. <https://doi.org/10.1016/j.bbadis.2017.01.020>
- [38] Triposkiadis, F., Briassoulis, A., Sarafidis, P., Magouliotis, D., Athanasiou, T., Paraskevaidis, I., Skoularigis, J., & Xanthopoulos, A. (2023). The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF. *Journal of clinical medicine*, 12(20), 6486. <https://doi.org/10.3390/jcm12206486>

- [39] Zucker, I. H., Xiao, L., & Haack, K. K. (2014). The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. *Clinical science (London, England : 1979)*, 126(10), 695–706. <https://doi.org/10.1042/CS20130294>
- [40] Peti-Peterdi, J., & Harris, R. C. (2010). Macula densa sensing and signaling mechanisms of renin release. *Journal of the American Society of Nephrology : JASN*, 21(7), 1093–1096. <https://doi.org/10.1681/ASN.2009070759>
- [41] Patel, S., Rauf, A., Khan, H., & Abu-Izneid, T. (2017). Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 94, 317–325. <https://doi.org/10.1016/j.biopha.2017.07.091>
- [42] Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018). Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. *Physiological reviews*, 98(3), 1627–1738. <https://doi.org/10.1152/physrev.00038.2017>
- [43] Richardson, W. J., Clarke, S. A., Quinn, T. A., & Holmes, J. W. (2015). Physiological Implications of Myocardial Scar Structure. *Comprehensive Physiology*, 5(4), 1877–1909. <https://doi.org/10.1002/cphy.c140067>
- [44] Ma, T. K., Kam, K. K., Yan, B. P., & Lam, Y. Y. (2010). Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. *British journal of pharmacology*, 160(6), 1273–1292. <https://doi.org/10.1111/j.1476-5381.2010.00750.x>
- [45] Garoffolo, G., & Pesce, M. (2021). From dissection of fibrotic pathways to assessment of drug interactions to reduce cardiac fibrosis and heart failure. *Current research in pharmacology and drug discovery*, 2, 100036. <https://doi.org/10.1016/j.crphar.2021.100036>
- [46] Chalise, U., & Hale, T. M. (2024). Fibroblasts under pressure: cardiac fibroblast responses to hypertension and antihypertensive therapies. *American journal of physiology. Heart and circulatory physiology*, 326(1), H223–H237. <https://doi.org/10.1152/ajpheart.00401.2023>
- [47] Garrido, A. M., & Griendling, K. K. (2009). NADPH oxidases and angiotensin II receptor signaling. *Molecular and cellular endocrinology*, 302(2), 148–158. <https://doi.org/10.1016/j.mce.2008.11.003>
- [48] Vasquez, F., Tiscornia, C., Lorca-Ponce, E., Aicardi, V., & Vasquez, S. (2025). Cardiorenal Syndrome: Molecular Pathways Linking Cardiovascular Dysfunction and Chronic Kidney Disease Progression. *International journal of molecular sciences*, 26(15), 7440. <https://doi.org/10.3390/ijms26157440>
- [49] Brown N. J. (2013). Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. *Nature reviews. Nephrology*, 9(8), 459–469. <https://doi.org/10.1038/nrneph.2013.110>
- [50] Wu, J., Pei, Y., Wu, J., & Huang, Y. (2025). Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials. *BMC cardiovascular disorders*, 25(1), 701. <https://doi.org/10.1186/s12872-025-05098-5>
- [51] Prasad, D., Drysch, A., Upadhyay, D., & Neilson, E. G. (2026). The Story of Aldosterone Escape. *Journal of the American Society of Nephrology : JASN*, 37(1), 164–171. <https://doi.org/10.1681/ASN.0000000908>
- [52] Park, J., Hamanaka, A., Park, I., & Abdelhady, H. G. (2025). Chronic β -Blockade and Systemic Homeostasis: Molecular Integration of Cardiorenal and Immune Pathways, a Narrative Review. *Biomolecules*, 15(12), 1653. <https://doi.org/10.3390/biom15121653>
- [53] Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018). The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). *Physiological reviews*, 98(1), 505–553. <https://doi.org/10.1152/physrev.00023.2016>
- [54] Simões e Silva, A. C., Silveira, K. D., Ferreira, A. J., & Teixeira, M. M. (2013). ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. *British journal of pharmacology*, 169(3), 477–492. <https://doi.org/10.1111/bph.12159>
- [55] Greenberg B. (2020). Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure. *International journal of heart failure*, 2(2), 73–90. <https://doi.org/10.36628/ijhf.2020.0002>

- [56] Shanks, J., & Ramchandra, R. (2021). Angiotensin II and the Cardiac Parasympathetic Nervous System in Hypertension. *International journal of molecular sciences*, 22(22), 12305. <https://doi.org/10.3390/ijms222212305>
- [57] King, V. L., English, V. L., Bharadwaj, K., & Cassis, L. A. (2013). Angiotensin II Stimulates Sympathetic Neurotransmission to Adipose Tissue. *Physiological reports*, 1(2), e00014. <https://doi.org/10.1002/phy2.14>
- [58] Goldsmith S. R. (2004). Interactions between the sympathetic nervous system and the RAAS in heart failure. *Current heart failure reports*, 1(2), 45–50. <https://doi.org/10.1007/s11897-004-0024-5>
- [59] Pawlonka, J., Buchalska, B., Buczman, K., Borzuta, H., Kamińska, K., & Cudnoch-Jędrzejewska, A. (2024). Targeting the Renin-angiotensin-aldosterone System (RAAS) for Cardiovascular Protection and Enhanced Oncological Outcomes: Review. *Current treatment options in oncology*, 25(11), 1406–1427. <https://doi.org/10.1007/s11864-024-01270-9>
- [60] Delrue, C., & Speeckaert, M. M. (2025). Beyond Blood Pressure: Emerging Pathways and Precision Approaches in Hypertension-Induced Kidney Damage. *International journal of molecular sciences*, 26(15), 7606. <https://doi.org/10.3390/ijms26157606>
- [61] De Angelis, E., Pecoraro, M., Rusciano, M. R., Ciccarelli, M., & Popolo, A. (2019). Cross-Talk between Neurohormonal Pathways and the Immune System in Heart Failure: A Review of the Literature. *International journal of molecular sciences*, 20(7), 1698. <https://doi.org/10.3390/ijms20071698>
- [62] Zheng, H., Li, Y. F., Wang, W., & Patel, K. P. (2009). Enhanced angiotensin-mediated excitation of renal sympathetic nerve activity within the paraventricular nucleus of anesthetized rats with heart failure. *American journal of physiology. Regulatory, integrative and comparative physiology*, 297(5), R1364–R1374. <https://doi.org/10.1152/ajpregu.00149.2009>
- [63] Cuadra, A. E., Shan, Z., Sumners, C., & Raizada, M. K. (2010). A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link?. *Pharmacology & therapeutics*, 125(1), 27–38. <https://doi.org/10.1016/j.pharmthera.2009.07.007>
- [64] Kishi, T., & Hirooka, Y. (2012). Central mechanisms of abnormal sympathoexcitation in chronic heart failure. *Cardiology research and practice*, 2012, 847172. <https://doi.org/10.1155/2012/847172>
- [65] Gomez-Sanchez E. P. (2011). Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?. *Trends in endocrinology and metabolism: TEM*, 22(5), 179–187. <https://doi.org/10.1016/j.tem.2011.02.001>
- [66] Parati, G., & Esler, M. (2012). The human sympathetic nervous system: its relevance in hypertension and heart failure. *European heart journal*, 33(9), 1058–1066. <https://doi.org/10.1093/eurheartj/ehs041>
- [67] Ames, M. K., Atkins, C. E., & Pitt, B. (2019). The renin-angiotensin-aldosterone system and its suppression. *Journal of veterinary internal medicine*, 33(2), 363–382. <https://doi.org/10.1111/jvim.15454>
- [68] Schlaich, M. P., Kaye, D. M., Lambert, E., Hastings, J., Campbell, D. J., Lambert, G., & Esler, M. D. (2005). Angiotensin II and norepinephrine release: interaction and effects on the heart. *Journal of hypertension*, 23(5), 1077–1082. <https://doi.org/10.1097/01.hjh.0000166850.80344.cf>
- [69] Schlaich, M. P., Kaye, D. M., Lambert, E., Sommerville, M., Socratous, F., & Esler, M. D. (2003). Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. *Circulation*, 108(5), 560–565. <https://doi.org/10.1161/01.CIR.0000081775.72651.B6>
- [70] Grassi, G., Seravalle, G., & Esler, M. (2020). Sympathomodulation in congestive heart failure: From drugs to devices. *International journal of cardiology*, 321, 118–125. <https://doi.org/10.1016/j.ijcard.2020.07.027>
- [71] Bayraktutan U. (2025). Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways. *Current issues in molecular biology*, 47(7), 501. <https://doi.org/10.3390/cimb47070501>
- [72] Llano-Diez, M., Sinclair, J., Yamada, T., Zong, M., Fauconnier, J., Zhang, S. J., Katz, A., Jardemark, K., Westerblad, H., Andersson, D. C., & Lanner, J. T. (2016). The Role of Reactive Oxygen Species in β -Adrenergic Signaling in Cardiomyocytes from Mice with the Metabolic Syndrome. *PloS one*, 11(12), e0167090. <https://doi.org/10.1371/journal.pone.0167090>

- [73] Sygitowicz, G., Maciejak-Jastrzębska, A., & Sitkiewicz, D. (2021). A Review of the Molecular Mechanisms Underlying Cardiac Fibrosis and Atrial Fibrillation. *Journal of clinical medicine*, 10(19), 4430. <https://doi.org/10.3390/jcm10194430>
- [74] Behnoush, A. H., Khalaji, A., Naderi, N., Ashraf, H., & von Haehling, S. (2023). ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. *ESC heart failure*, 10(3), 1531–1544. <https://doi.org/10.1002/ehf2.14255>
- [75] Masarone, D., Martucci, M. L., Errigo, V., & Pacileo, G. (2021). The Use of β -Blockers in Heart Failure with Reduced Ejection Fraction. *Journal of cardiovascular development and disease*, 8(9), 101. <https://doi.org/10.3390/jcdd8090101>
- [76] Saleem, T. S., Bharani, K., & Gauthaman, K. (2010). ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease. *Open access emergency medicine : OAEM*, 2, 51–59. <https://doi.org/10.2147/oaem.s10507>
- [77] Chilton, R. J., & Silva-Cardoso, J. (2023). Mineralocorticoid receptor antagonists in cardiovascular translational biology. *Cardiovascular endocrinology & metabolism*, 12(3), e0289. <https://doi.org/10.1097/XCE.0000000000000289>
- [78] von Lueder, T. G., Sangaralingham, S. J., Wang, B. H., Kompa, A. R., Atar, D., Burnett, J. C., Jr, & Krum, H. (2013). Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. *Circulation. Heart failure*, 6(3), 594–605. <https://doi.org/10.1161/CIRCHEARTFAILURE.112.000289>
- [79] Müller-Werdan, U., Stöckl, G., & Werdan, K. (2016). Advances in the management of heart failure: the role of ivabradine. *Vascular health and risk management*, 12, 453–470. <https://doi.org/10.2147/VHRM.S90383>
- [80] Neshat, S., Moradi, H., Bidares, M., Heidari, A., Falahati Marvast, A., Ortega, R., & Heshmat, K. (2025). Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lipid Modulation in Heart Failure: A Narrative Review. *Cureus*, 17(12), e99752. <https://doi.org/10.7759/cureus.99752>
- [81] Subhani, M. K., Sabani, A., Omer, O., Kheirelsid, F., & Srour, A. K. (2025). Impact of Renin-Angiotensin-Aldosterone System Modulation on Cognitive and Neuropsychiatric Outcomes: A Systematic Review of Clinical and Mechanistic Evidence. *Cureus*, 17(7), e87557. <https://doi.org/10.7759/cureus.87557>
- [82] Palaparthi, E. C., Padala, T., Singamaneni, R., Manaswini, R., Kantula, A., Aditya Reddy, P., Chandini, P., Sathwika Eliana, A., Siri Samhita, P., & Patnaik, P. K. (2025). Emerging Therapeutic Strategies for Heart Failure: A Comprehensive Review of Novel Pharmacological and Molecular Targets. *Cureus*, 17(4), e81573. <https://doi.org/10.7759/cureus.81573>
- [83] Paraskevaidis, I., Tsougos, E., & Kourek, C. (2025). One Syndrome, Many Faces: A Unified Perspective on Heart Failure Phenotypes. *International journal of molecular sciences*, 26(18), 8960. <https://doi.org/10.3390/ijms26188960>
- [84] Amekran, Y., Damoun, N., & El Hangouche, A. J. (2025). A focus on the assessment of the autonomic function using heart rate variability. *Global cardiology science & practice*, 2025(1), e202512. <https://doi.org/10.21542/gcsp.2025.12>
- [85] Petrescu, M., Văcărescu, C., Tudoran, C., Iurciuc, S., & Cozma, D. (2026). Precision Medicine in Heart Failure: Integrating Ventricular-Vascular Interaction and Arterial Stiffness into Patient Phenotyping. *Journal of clinical medicine*, 15(9), 3212. <https://doi.org/10.3390/jcm15093212>
- [86] Fisher, J. P., Young, C. N., & Fadel, P. J. (2009). Central sympathetic overactivity: maladies and mechanisms. *Autonomic neuroscience : basic & clinical*, 148(1-2), 5–15. <https://doi.org/10.1016/j.autneu.2009.02.003>
- [87] Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025). Oxidative Stress: Signaling Pathways, Biological Functions, and Disease. *MedComm*, 6(7), e70268. <https://doi.org/10.1002/mco2.70268>
- [88] Ajjola, O. A., Aksu, T., Arora, R., Biaggioni, I., Chen, P. S., De Ferrari, G., Dusi, V., Fudim, M., Goldberger, J. J., Green, A. L., Herring, N., Khalsa, S. S., Kumar, R., Lakatta, E., Mehra, R., Meyer, C., Po, S., Stavrakis, S., Somers, V. K., Tan, A. Y., ... Shivkumar, K. (2025). Clinical neurocardiology: defining the value of neuroscience-based cardiovascular therapeutics - 2024 update. *The Journal of physiology*, 603(7), 1781–1839. <https://doi.org/10.1113/JP284741>

- [89] Fuller, P. J., Yang, J., Young, M. J., & Cole, T. J. (2025). Mechanisms of ligand-mediated modulation of mineralocorticoid receptor signaling. *Molecular and cellular endocrinology*, 600, 112504. <https://doi.org/10.1016/j.mce.2025.112504>
- [90] Murga, C., Arcones, A. C., Cruces-Sande, M., Briones, A. M., Salaices, M., & Mayor, F., Jr (2019). G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases. *Frontiers in pharmacology*, 10, 112. <https://doi.org/10.3389/fphar.2019.00112>
- [91] Zablocki, D., & Sadoshima, J. (2013). Angiotensin II and oxidative stress in the failing heart. *Antioxidants & redox signaling*, 19(10), 1095–1109. <https://doi.org/10.1089/ars.2012.4588>
- [92] Sultan, D., & Brundel, B. J. J. M. (2026). Mechanisms of Atrial Fibrillation in Heart Failure: Uncovering Therapeutic Targets in the Atrial Substrate. *Current heart failure reports*, 10.1007/s11897-026-00744-1. Advance online publication. <https://doi.org/10.1007/s11897-026-00744-1>
- [93] Jhund, P. S., & McMurray, J. J. (2016). The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. *Heart (British Cardiac Society)*, 102(17), 1342–1347. <https://doi.org/10.1136/heartjnl-2014-306775>
- [94] Feng, Q., Wu, M., & Mai, Z. (2025). Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes. *Frontiers in cardiovascular medicine*, 12, 1482918. <https://doi.org/10.3389/fcvm.2025.1482918>
- [95] Lee, J., Oh, J., Ha, J., Lee, C. J., & Kang, S. M. (2025). Achieved targeted heart rate following ivabradine therapy correlates with left ventricular reverse remodeling in non-ischemic dilated cardiomyopathy. *Scientific reports*, 15(1), 33043. <https://doi.org/10.1038/s41598-025-09352-w>
- [96] Che, H., Gao, Y., Xu, Y., Xu, H., Eils, R., & Tian, M. (2026). Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases. *Signal transduction and targeted therapy*, 11(1), 8. <https://doi.org/10.1038/s41392-025-02329-1>
- [97] Ansari, R. A., Senapati, S. G., Ahluwalia, V., Panjwani, G. A. R., Kaur, A., Yerrapragada, G., Jayapradhaban Kala, J., Elangovan, P., Karuppiyah, S. S., Asadimanesh, N., Muthyala, A., & Arunachalam, S. P. (2025). Artificial Intelligence-Guided Neuromodulation in Heart Failure with Preserved and Reduced Ejection Fraction: Mechanisms, Evidence, and Future Directions. *Journal of cardiovascular development and disease*, 12(8), 314. <https://doi.org/10.3390/jcdd12080314>